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Abstract
Background: The effectiveness of ginseng in preventing and treating various central nervous system (CNS)
diseases has been widely confirmed. However, ginsenosides, the principal components of ginseng, are
characterized by poor accessibility to the brain, and this pharmacokinetic-pharmacological paradox remains poorly
explained. Anti-inflammatory approaches are becoming promising therapeutic strategies for depression and other
CNS diseases; however, previous studies have focused largely on anti-inflammatory therapies directed at the central
nervous system. It is thus of interest to determine whether ginsenosides, characterized by poor brain distribution,
are also effective in treating lipopolysaccharide- (LPS) induced depression-like behavior and neuroinflammation.
Methods: In an LPS-induced depression-like behavior model, the antidepressant effects of ginseng total saponins
(GTS) were assessed using a forced swimming test, a tail suspension test, and a sucrose preference test. The anti-
inflammatory efficacies of GTS in brain, plasma, and LPS-challenged RAW264.7 cells were validated using ELISA and
quantitative real-time PCR. Moreover, indoleamine 2,3-dioxygenase (IDO) activity in the periphery and brain were
also determined by measuring levels of kynurenine/tryptophan.
Results: GTS significantly attenuated LPS-induced depression-like behavior. Moreover, LPS-induced increases in 5-
HT and tryptophane turnover in the brain were significantly reduced by GTS. IDO activities in brain and periphery
were also suppressed after pretreatment with GTS. Furthermore, GTS-associated recovery from LPS-induced
depression-like behavior was paralleled with reduced mRNA levels for IL-1b, IL-6, TNF-a, and IDO in hippocampus.
Poor brain distribution of ginsenosides was confirmed in LPS-challenged mice. GTS treatment significantly
decreased production of various proinflammatory cytokines in both LPS-challenged mice and RAW264.7 cells.
Conclusion: This study suggests that the anti-depression efficacy of GTS may be largely attributable to its
peripheral anti-inflammatory activity. Our study also strengthens an important notion that peripheral anti-
inflammation strategies may be useful in the therapy of inflammation-related depression and possibly other CNS
diseases.
Background
Depression is a worldwide problem for humans due to
its relatively high lifetime prevalence and its substantial
associated disability [1-3]. Commonly used antidepres-
sants, including selective serotonin (5-HT) reuptake
inhibitors (SSRIs) and monoamine oxidase inhibitors
(MAOs), are effective [4]; however, their therapeutic
effects only manifest in 28%-63% of depressed patients
[5]. The classic monoamine hypothesis of depression
has been challenged, and alternative therapeutic strate-
gies based on novel understandings of the etiology of
depression are urgently needed.
Accumulating evidence reveals a close linkage between
inflammation and depression. Depressive symptoms fre-
quently develop in chronically infected patients and in
patients with inflammatory bowel disease, chronic
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any medium, provided the original work is properly cited.kidney disease, or rheumatoid arthritis [6-9]. Moreover,
an imbalance between pro-inflammatory cytokines (IL-
1b,I L - 6 ,I F N - g,a n dT N F - a) and anti-inflammatory
cytokines (IL-4 and IL-10) is frequently observed in
untreated depressed patients [10,11], and increased
levels of pro-inflammatory cytokines have been found to
correlate well with severity of depression [12]. Although
the detailed molecular mechanisms underlying inflam-
mation-related depression remain unclear, it has been
suggested that pro-inflammatory cytokines may affect
the catabolism and disposition of various neurotransmit-
ters through activation of IDO [13,14] and/or by up-reg-
ulation of the serotonin transporter [15-17].
Inflammation-induced IDO activation results in an
increased turnover rate for tryptophan, and subsequent
accumulation of neurotoxic metabolites such as kynure-
nine and quinolinic acid, ultimately leading to the devel-
opment of depression [18].
Because of the close link between peripheral inflam-
mation and depression, it is reasonable to predict a ben-
eficial effect of anti-inflammatory therapy on
depression-like behavior. Indeed, the non-steroidal anti-
inflammatory drug (NSAID) celecoxib has been proven
effective in attenuating chronic and unpredictable
stress-induced depression-like behavior, indicating that
NSAIDs may be useful for the therapy of depression
[19]. Some clinical trials and open-label studies also
have found that some NSAIDs can reduce depressive
symptoms, in particular fatigue, and improve quality of
life [20]. In view of the fact that these drugs distribute
efficiently into the central nervous system, it remains
uncertain whether peripheral anti-inflammatory therapy
might also be effective in producing neuroprotective
effects. This idea is of great potential significance in the
development of novel CNS drugs because it is always
difficult to balance pharmacokinetic and pharmacologi-
cal performances during the process of drug design [21].
Ginseng, the root of Panax ginseng C.A. Meyer,i sf r e -
quently and widely used as a tonic herb, and ranks the
most widely taken herbal medicine in the world [22].
Saponins, also named ginsenosides, are considered
responsible for most of the therapeutic benefits of gin-
seng. Ginseng total saponins (GTS) have been widely
confirmed to be effective in preventing and treating var-
ious CNS diseases. GTS exhibit anxiolytic-like effects in
an elevated plus-maze model [23,24], and GTS’sa n t i d e -
pressant-like effects have been reported [25]. In addi-
tion, GTS can improve the outcome of cerebral
ischemia [26], attenuate neuroinflammation [27], and
prevent learning and memory deficits during aging [28].
On the other hand, previous studies by us and others
have shown that brain tissue levels achieved for most of
the ginsenosides are very low [29,30], and that these are
unlikely to reach the concentrations necessary to elicit
neuroprotective effects. Such a pharmacokinetics/phar-
macological paradox questions the currently well
acknowledged concept that CNS drugs should distribute
well into the brain to elicit direct neuroprotective
effects. Based on the close link between peripheral
inflammation and depression, we hypothesized that the
central therapeutic effects of GTS might derive from
peripheral anti-inflammation activities. To confirm this
hypothesis, we developed a peripheral LPS-induced
depression mouse model to determine both anti-depres-
sion and anti-inflammatory effects of GTS in the periph-
e r ya n di nt h eC N S .T of u r t h e rv e r i f yo u rh y p o t h e s i s ,
the plasma pharmacokinetics and brain distribution of
major GST markers were determined in peripherally
LPS-challenged mice.
Methods
Drugs and reagents
GTS was purchased from the Department of Natural
Medical Chemistry, School of Chemistry, Jilin University
(Changchun, China); the contents of the major ginseno-
sides (Rb1 19.1%, Rb2 and Rb3 13.8%, Rc 12.3%, Rd
9.7%, Re 11.8%, Rf 3.5%, Rg1 7.1% and Rh1 0.7%) were
determined using a validated LC-MS method in our
laboratory. LPS (L-3129, 0127:B8) was purchased from
Sigma (St Louis, MO, USA).
Animals and treatment
Male CD-1 mice (10-12 week old, 27-30 g) were pur-
chased from the Animal Centre of China Pharmaceuti-
cal University. They were individually housed in
polypropylene cages and maintained at controlled tem-
perature (~23°C) and relatively humidity (45-55%) under
a normal 12 h light/dark cycle (lights on at 08:00 a.m.)
with ad libitum access to food and water. Mice were
handled 2 min each day for 7 days before experimenta-
tion to acclimate them to routine handing. All animal
studies were approved by the Animal Ethics Committee
of China Pharmaceutical University.
For all studies, LPS solutions were freshly prepared in
sterile endotoxin-free saline and administered intraperi-
toneally. The dose of LPS (0.8 mgkg
-1) was selected
because it could induce an acute sickness response in 4
h and reliable depression-like behavior at 24 h post-LPS
challenge [13,31]. GTS, dissolved in saline, was intragas-
trically administered (200 mg.kg
-1) once daily for 7 days
prior to, and on the same day of, LPS injection. One set
of animals was used for behavioral testing, including an
open field test, a tail suspension test, and a forced swim-
ming test. In another set of mice, brain samples were
collected for analysis of 5-HT, tryptophan, and their
metabolites at 24 h post LPS challenge (n = 10). Plasma
was also collected for analysis of peripheral IDO activity.
I nas u b s e q u e n ts t u d y ,as u c r o s ep r e f e r e n c et e s tw a s
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Mice were then sacrificed and the hippocampi were
immediately collected for analysis of mRNA levels for
proinflammatory cytokines (IL-1b,I L - 6 ,a n dT N F - a)
and IDO using quantitative real-time PCR. In the final
study, mice were injected i.p. with saline or LPS; 4 h
later, mice were killed and plasma was collected and
stored frozen (-80°) until analyzed for proinflammatory
cytokines and corticosterone (n = 8).
Behavior tests
Sucrose preference, tail suspension, and forced swim-
ming tests were employed for behavior tests. Food
intake and body weight changes were also recorded at
22 h post LPS injection.
Open field test
The open field test was performed before the formal
experiments. The cage was divided into nine virtual
quadrants, and locomotor activity was measured by
counting the number of line crossings and rearings dur-
ing a 5-min period. Counting was done by two well-
trained observers who were blind to the treatments.
Sucrose preference test
The sucrose preference test [32,33] was employed to
evaluate anhedonia. Before testing, all mice were accli-
mated to drinking water and 2% sucrose solution in 50
ml conical tubes for 3 days. On the day of testing,
drinking water and 2% sucrose solution were placed in
t h eh o m ec a g eo v e r n i g h t ,f o l l o w e db yf o o da n dw a t e r
deprivation for 2 h prior to the testing. At the end of
the testing, fluid content was measured and sucrose pre-
ference was calculated using the following equation:
Sucrose preference (%) = sucrose intake/(sucrose intake
+ water intake) × 100.
Forced swimming test (FST)
The FST was carried out as previously described [34] with
slight modifications. Briefly, mice were placed individually
in a clear cylinder (diameter 10 cm, height 25 cm), con-
taining 15 cm of water at 25 ± 1°C. The water was chan-
ged between testing sessions. Mice were forced to swim
for 6 min, and the immobility time during the last 5 min
was manually measured by a blinded observer. Mice were
considered immobile when they ceased struggling,
remained floating motionless, and only made those move-
ments necessary to keep their head above the water [35].
Tail suspension test (TST)
The TST was conducted as previously described [36].
Briefly, mice were suspended by adhesive tape that was
positioned about 2.5 cm from the tail tap with the head
40 cm above the floor. The trial was carried out for 6
min and the duration of immobility was manually
recorded by two blinded observers during the final 5
min interval of the test. Mice were considered immobile
when they hung passively and motionlessly.
Determination of 5-HT, tryptophan, and their metabolites
M o u s eb r a i n s( a b o u t1 0 0m g )w e r ef i r s tw e i g h e da n d
sonicated in 400 μlo f0 . 1MH C l O 4/10 μMa s c o r b a t e
solution for 1 min, and then the brain samples were
centrifuged at 12,000 g for 15 min at 4°C. An aliquot of
20 μl of supernatant was injected to a reverse-phase
high performance liquid chromatograph (HPLC)
equipped with electrochemical detection (Shimadzu,
Japan) for the determination of 5-HT and 5-hydroxyin-
doleacetic acid (5-HIAA). Levels of TRP and KYN were
detected by a UV detector at 225 nm (for TRP) and 360
nm (for KYN) wavelengths. Concentrations were
expressed as ng/g of wet tissue weight. The turnover
rate of 5-HT (5-HIAA/5-HT) and Tryptophan (KYN/
TRP) was also calculated [13].
Plasma corticosterone determination
Quantification of plasma corticosterone was performed
using an LC-ESI-MS method based on a previous report
[37] with minor modifications. The sensitivity (lower
limits of quantification) of the corticosterone assay was
10 ng/ml. Intra- and inter-assay coefficients of variation
were less than 10%.
Cytokine enzyme-linked immunosorbent assays (ELISAs)
IL-1b, IL-6, and TNF-a in plasma were measured using
a commercially available ELISA kit (Excell, Shanghai,
China). Assays were sensitive with lower limits of quan-
tification at 10 pg/ml for IL-1b, IL-6, and TNF-a; inter-
and intra-assay coefficients of variation were less than
10%.
Quantitative real-time PCR
Total RNA from hippocampal samples was extracted in
Trizol reagent (Takara, Dalian, China). All reverse tran-
scriptase reactions were carried out by using a Takara
PrimeScript 1st Strand cDNA Synthesis Kit according to
the manufacturer’s instructions.
Real-time PCR analysis was performed in a Thermal
Cycler Dice™ Real Time System (Takara, Japan). The
sequences of primers used in this experiment are sum-
marized as follows: IL-1b,s e n s e5 ’-CTGTGTCTT TCC
CGT GGA CC-3’;a n t i s e n s e5 ’- CAG CTC ATA TGG
GTC CGA CA-3’;I L - 6 ,s e n s e5 ’- CCA GAA ACC GCT
ATG AAG TTC CT -3’;a n t i s e n s e5 ’-C A CC A GC A T
CAG TCC CAA GA -3’;T N F - a,s e n s e5 ’-A T CC G C
GAC GTG GAA CTG -3’; antisense 5’- CAG CTC ATA
TGG GTC CGA CA-3’;I D O ,s e n s e5 ’-GTA CAT CAC
CAT GGC GTA TG-3’;a n t i s e n s e5 ’- ACC GCC TGG
AGT TCT GGA A -3’; b-actin, sense 5’-TCT GGC
ACC ACA CCT TCT A-3’; and antisense 5’-AGG CAT
ACA GGG ACA GCA C-3’.T h eS Y B RG r e e nIP C R
mix kit (Takara, Japan) was used to quantify gene
expression. LightCycler reactions were performed in a
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instructions. Three replicates were performed for each
quantitative PCR run.
The mRNA concentrations of all detected genes were
normalized to that of b-actin in each sample (using the
delta-delta Ct method). Results are expressed as fold
change relative to the vehicle group (saline-treated
mice).
Pharmacokinetics and brain distribution of GTS in mice
Following intragastric administration of GTS (200 mg/
kg, once daily) for 6 days, GTS and LPS were admini-
strated simultaneously on the 7
th day. Mice were then
sacrificed at indicated time points (3-4 mice per time
point), and plasma and brain samples were collected.
Samples of brain tissues were rinsed, dried, and
weighted, and 100 mg of each brain tissue sample was
ultrasonicated in 200 μl physiological saline. After cen-
trifugation at 10000 g for 5 min, supernatant were col-
lected and analyzed using a validated LC-MS method
with small modifications.
Cell culture and treatment
Raw264.7 cell-based proinflammatory cytokine inhibition
assay
The murine macrophage cell line, Raw264.7, was cul-
tured in Dulbecco’s modified Eagle’s medium supple-
mented with 2 mM glutamine, penicillin G (100 U/ml),
streptomycin (100 μg/ml), and 10% fetal bovine serum,
and maintained at 37°C in a humidified incubator con-
taining 5% CO2. Cells were pre-treated with 1, 5, 20, or
100 μg/ml GTS for 0.5 h, and then co-incubated with
100 ng/ml of LPS for another 24 h. TNF-a and IL-6
levels, in supernatants collected from GTS-treated cells,
were measured with an ELISA kit. Samples were ana-
lyzed according to the protocols described above.
A549 cell-based IDO-1 inhibitory activity assay
A549 cells were maintained in RPMI-1640 supplemen-
ted with 100 U/mL penicillin, 100 mg/ml streptomycin,
and 10% fetal bovine serum (Gibco-Invitrogen, USA).
Cells were cultured at 37°C with 5% CO2 and 95%
humidity. For the IDO-1 inhibitory activity assay, A549
cells were seeded in 24-well culture plates with ~80%
confluence. hIFN-g (200 U/ml) and were used to induce
IDO expression. After 24 h of induction, test com-
pounds at the indicated concentrations were added and
incubated for another 5 h, and then 200 μlo fs u p e r n a -
tant per well was collected to determine the concentra-
tion of kynurenine. IDO activity was expressed as pmol/
h.mg protein.
RBE4 cell-based LAT-1 inhibition assay
RBE4 cells represent an immortalized rat brain endothe-
lial cell line that expresses high levels of LAT-1 [38].
RBE4 cells were grown on rat tail collagen-coated, 24-
well plates or tissue culture flasks in medium consisting
of Ham’sF 1 0a n da-MEM (1:1, volume/volume), sup-
plemented with fetal bovine serum (Gibco-Invitrogen,
USA), 100 U/mL penicillin, and 100 mg/ml streptomy-
cin. For the LAT-1 inhibition assay, cells were equili-
brated for 20 min at 37°C in a buffered salt solution
before uptake experiments. Uptake was initiated by add-
ing 1 ml of pre-warmed buffer containing 30 μMo f
KYN and GTS (1-100 μg/ml) or a competitive inhibitor
of LAT-1, BCH (Sigma, 400 μM). After incubation for
10 min at 37°C, uptake was terminated by washing the
cultures with ice-cold phosphate-buffered saline 3 times.
Cell lysates were collected for KYN analysis and protein
content determination.
Statistical analyses
Data are expressed as mean ± SEM for the indicated
analyses. Two-way analysis of variance [39] was
employed to determine significant main effects and
interactions between main factors. When appropriate,
differences between groups were evaluated by an F pro-
tected t-test. For all of the analyses, a value of p < 0.05
was considered statistically significant.
Results
GTS improves LPS-associated anorexia and weight loss
As illustrated in Figure 1, GTS × LPS interactions were
significantly different for both food intake (F1,16 =
19.564, p < 0.01, Figure 1A) and body weight changes
(F1,36 = 12.804, p < 0.01, Figure 1B) at 24 h post-LPS
challenge. Food intake and body weight were signifi-
cantly reduced in LPS-treated mice as compared with
vehicle-treated mice (p < 0.01 for each), whereas mice
pretreated with GTS at a dose of 200 mg/kg showed sig-
nificant protective effect against LPS-associated anorexia
(p < 0.05) and weight loss (p < 0.05).
GTS attenuates LPS-induced depression-like behavior
Locomotor activity tests were performed to exclude the
possibility of a nonspecific stimulant action of GTS that
could create false-positive results for the FST and TST.
As indicated in Figure 2A, there were no significant dif-
ferences in rearings numbers and movement numbers
among different groups.
Sucrose preference index, tail suspension, and forced
swimming tests were performed to determine LPS-
induced depression-like beha v i o r .A ss h o w ni nF i g u r e
2B, there was a significant GTS × LPS interaction in
s u c r o s ep r e f e r e n c e( F 1,16 = 6.102, P < 0.05). LPS-chal-
lenged mice exhibited a decreased sucrose preference
index as compared with vehicle-challenged mice (P <
0.01), whereas pretreatment with GTS (200 mg/kg) sig-
nificantly increased the sucrose preference index as
compared with mice in the vehicle/LPS group (p <
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test and forced swimming test. As shown in Figure 2C
and 2D, there was a significant GTS × LPS interaction
in both TST (F1,36 = 5.239, P < 0.05) and FST (F1,36 =
4.737, P < 0.05) for immobility duration. LPS-induced
increases in immobility duration in the TST (p < 0.01)
and FST (p < 0.01) could be significantly attenuated by
GTS pretreatment (p < 0.05 for TST and p < 0.05 for
FST).
Corticosterone levels were determined as an indicator
of HPA activation. Figure 2E shows the effect of GTS
treatment on serum corticosterone levels in LPS-chal-
lenged mice. Two-way ANOVA revealed a significant
GTS × LPS interaction in serum corticosterone levels
(F1,28 = 21.933, p < 0.01). LPS caused a significant
increase in serum corticosterone levels in mice as
compared with saline-treated mice (p < 0.01). GTS
treatment decreased serum corticosterone levels in LPS-
challenged mice (P < 0.05) as compared with mice in
the vehicle/LPS group.
GTS reduces LPS-induced neuroinflammation and IDO
expression
Neuroinflammation-induced upregulation of IDO
expression and activity has been recently verified as an
important mechanism of peripheral LPS-induced
depression. To investigate whether GTS pretreatment is
effective against LPS-induced neuroinflammation, we
analyzed proinflammatory cytokines and IDO mRNA
expression in hippocampal samples collected 24 h post-
LPS challenge. As shown in Figure 3A, B and 3C, there
was a significant GTS × LPS interaction for the mRNA
expressions of IL-1b,I L - 6 ,a n dT N F - a (IL-1b:F 1,20 =
5.603, P < 0.05; IL-6: F1,20 = 6.955, p < 0.05, TNF-a:
F1,20 = 5.505, p < 0.05). Peripheral LPS markedly
increased the mRNA expressions of proinflammatory
cytokines (IL-1b: P < 0.01; IL-6: p < 0.01, TNF-a:p<
0.01) as compared with the control group. GTS pretreat-
m e n ta tad o s eo f2 0 0m g / k gs i g n i f i c a n t l ya t t e n u a t e d
LPS-induced mRNA upregulation of various proinflam-
matory cytokines (IL-1b: P < 0.05; IL-6: p < 0.05, TNF-
a: p < 0.05).
IDO mRNA levels were determined from the same
RNA pool. Figure 3D shows a significant GTS × LPS
interaction for mRNA expression of IDO (F1,20 =6 . 3 0 3 ,
p < 0.05). LPS challenge significantly increased IDO
mRNA expression in hippocampus (P < 0.01). LPS-
induced upregulation of IDO mRNA expression was
attenuated by GTS pretreatment at a dose of 200 mg/kg
in the hippocampus (p < 0.05), as compared with vehi-
cle/LPS group.
GTS attenuates LPS-induced metabolic disorders of TRP
and 5-HT
TRP, 5-HT, and their metabolites levels are summarized
in Table 1. In line with previous reports, the present
study shows that brain concentrations of KYN and 5-
HIAA are significantly increased after LPS challenge.
GTS pretreatment (200 mg/kg) significantly ameliorated
LPS-induced alternations of KYN and 5-HIAA levels (P
< 0.05 for each). In addition, GTS at a dose of 200 mg/
kg reduced the increased turnover rate of TRP and 5-
HT in the brain (p < 0.05 for each).
GTS reduces LPS-induced peripheral inflammation and
kynurenine/tryptophan ratio
Effects of GTS on regulating plasma proinflammatory
cytokines in differently treated mice are shown in Figure
4. Two-way ANOVA showed significant GTS × LPS
interactions for the plasma levels of these
Figure 1 GTS improves LPS-associated anorexia and weight
loss. Mice were administered orally with GTS at a dosage of 200
mg.kg
-1 which was dissolved in saline once daily for 7 days prior to
and on the same day of LPS injection. Immediately following the
final injection, mice also received either an i.p. injection of sterile
endotoxin-free saline or LPS (0.8 mgkg
-1). The 22-h change in food
intake (Figure.1A) and body weight loss (Figure.1B) following LPS
administration were measured. The data are expressed as mean ±
SEM. For statistical significance, a: p < 0.01 compared with the
vehicle/saline group, b: p < 0.05 compared with the vehicle/LPS
group. c: p < 0.01 compared with the LPS/GTS group.
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activity, expressed as rearings numbers and movement numbers (Figure.2A, n = 10 mice each group), was assessed before the tail suspension
test (TST) and the forced swimming test (FST). The sucrose preference test was measured 24 h following administration of LPS (Figure.2B, n = 6
mice each group). Immobility time was assessed during the FST (Figure.2C, n = 10 mice each group) and the TST (Figure.2D, n = 10 mice each
group) 22 h and 24 h post-LPS injection. Corticosterone profiles in different groups which were determined 4 h post LPS or saline challenge
(Figure.2E, n = 8 mice each group C). The data are expressed as mean ± SEM. For statistical significance, a: p < 0.01 compared with the vehicle/
saline group, b: p < 0.05 compared with the vehicle/LPS group. c: p < 0.01 or p < 0.05 compared with the LPS/GTS group.
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1b:F 1,28 = 5.144 p < 0.05; IL-6: F1,28 = 6.143, p < 0.05;
TNF-a:F 1,28 = 5.471, p < 0.05). In mice pretreated with
vehicle, LPS markedly increased plasma levels of proin-
flammatory cytokines (IL-1b: P < 0.01; IL-6: p < 0.01,
TNF-a: p < 0.01) as compared with the control group at
4 h post-LPS challenge. GTS pretreatment at a dose of
200 mg/kg significantly reduced plasma levels of various
proinflammatory cytokines (IL-6: p < 0.05, TNF-a < 0.05,
IL-1b < 0.05) as compared with the vehicle/LPS group.
Increased peripheral levels of KYN may be an etio-
genic factor for the depression-like behavior in this
model. Figure 5A shows a significant GTS × LPS inter-
action in peripheral KYN concentrations (F1,36 =
Figure 3 GTS reduces LPS-induced neuroinflammation and IDO mRNA levels. Hippocampi were collected 24 h post-LPS challenge and
subjected to RNA extraction and Q-RT-PCR. mRNA expression of IL-1b, IL-6, TNF-a, and IDO in hippocampus are presented in Figures 3A, 3B, 3C,
and 3D (n = 6 mice each group). The data are expressed as mean ± SEM. For statistical significance, a: p < 0.01 compared with the vehicle/
saline group, b: p < 0.05 compared with the vehicle/LPS group. c: p < 0.01 or p < 0.05 compared with the LPS/GTS group.
Table 1 Effects of GTS administration on the concentrations of TRP, 5-HT, and their metabolites in brain; and on the
turnover of TRP and 5-HT (expressed as KYN/TRP and 5-HIAA/5-HT ratios, respectively) (n = 10)
nmol/g brain tissue Vehicle/Saline Vehicle/LPS GTS/Saline GTS/LPS
KYN 0.27 ± 0.03 1.06 ± 0.07
a 0.29 ± 0.03
c 0.77 ± 0.04
b
TRP 10.27 ± 0.41 11.75 ± 0.44 10.67 ± 0.38 11.21 ± 0.32
5-HIAA 0.95 ± 0.06 1.67 ± 0.13
a 1.00 ± 0.11
c 1.34 ± 0.05
b
5-HT 2.70 ± 0.05 2.93 ± 0.21 2.77 ± 0.14 2.93 ± 0.11
KYN/TRP 0.026 ± 0.002 0.091 ± 0.006
## 0.027 ± 0.002
c 0.067 ± 0.004
b
5-HIAA/5-HT 0.35 ± 0.03 0.57 ± 0.02
## 0.37 ± 0.03
c 0.46 ± 0.02*
Dates are expressed as mean ± SEM.
a: p < 0.01 compared with Vehicle/Saline treated mice
b: p < 0.05 compared with Vehicle/LPS treated mice
c: p < 0.05 or p < 0.01 compared with GTS/LPS treated mice.
Kang et al. Journal of Neuroinflammation 2011, 8:100
http://www.jneuroinflammation.com/content/8/1/100
Page 7 of 1411.002, p < 0.01). LPS challenge significantly increased
peripheral KYN concentrations (P < 0.01). GTS at a
dosage of 200 mg/kg could significantly reduce the
increased peripheral KYN concentrations in LPS-treated
mice (p < 0.01).
A ss h o w ni nF i g u r e5 B ,t h e r ew a sas i g n i f i c a n tG T S×
LPS interaction tested by two-way ANOVA (F1,36 = 8.719,
p < 0.01) in KYN/TRP ratios. As expected, we found that
the ratio of KYN/TRP was significantly increased in vehi-
cle/LPS treated mice, as compared with control mice. Mice
pretreated with GTS at a dose of 200 mg/kg showed a sig-
nificantly decreased ratio of KYN/TRP (p < 0.05) as com-
pared with mice in the vehicle/LPS group.
Ginsenosides shows poor brain penetration
To further confirm our hypothesis that ginsenosides are
unlikely to achieve effective concentrations in brain, the
pharmacokinetics and brain distributions of major
ginsenosides were determined in LPS-challenged mice. As
shown in Figure 6A, the plasma profiles of protopanaxa-
diol-type ginsenoside Rb1, Rb2 (Rb3), Rc, and Rd were
successfully characterized after an intragastric administra-
tion of GTS (200 mg/kg). The maximum concentrations
(Cmax) of the four major ginsenosides reached levels above
1 μg/ml, and their elimination half-life times (t1/2)w e r e
relatively long (> 20 h), suggesting that the plasma expo-
sure levels of ginsenosides would be sufficient to exert
their peripheral anti-inflammatory activities (Figure 6B).
However, most of the ginsenosides were undetectable in
the brain. Rb1, Rb2 (Rb3), Rc, and Rd were detectable but
at extremely low levels of < 20 ng/g wet tissue (Figure 6C).
GTS inhibits the production of proinflammatory cytokines
in LPS-stimulated RAW264.7 cells
The murine macrophage cell line, Raw264.7 cells, was
employed to verify the peripheral anti-inflammatory
Figure 4 Effects of GTS on plasma proinflammatory cytokines levels in different groups post LPS or saline challenge. Mice were treated
as in Figure 1. Plasma was collected 4 h after saline or LPS challenge. Cytokines were determined using commercial ELISA kits. The plasma
concentrations of IL-1b, IL-6, and TNF-a 4 h post LPS or saline challenge are represented in Figures 4A, 4B, and 4C (n = 8 mice for each group).
The data are expressed as mean ± SEM. For statistical significance, a: p < 0.01 compared with the vehicle/saline group, b: p < 0.05 compared
with the vehicle/LPS group. c: p < 0.01 or p < 0.05 compared with the LPS/GTS group.
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Page 8 of 14effects of GTS. As shown in Figure 7A and 7B, GTS had
no effect on the basal production of TNF-a and IL-6 in
RAW264.7 cells. In contrast, GTS treatment significantly
counteracted LPS-stimulated production of TNF-a and
IL-6 in RAW264.7 cells in a concentration-dependent
manner. Concentrations of major ginsenosides in GTS
applied were in a range of 1~100 μg/ml, which is com-
parable with those detected in mouse plasma.
GTS has no direct effect on LAT-1 or IDO activity
Because GTS pretreatment was effective in ameliorating
LPS-stimulated KYN increases in brain, it was of inter-
est to determine whether or not GTS could directly
influence the catabolism and transport of KYN. Presum-
ably, the inhibition of IDO and/or LAT-1 mediated
KYN transport across BBB could decrease KYN levels in
brain. To address this concern, the effects of GTS on
regulating KYN transport and IDO activity were deter-
mined in rBE4 cells and A549 cells, respectively.
We used rBE4 cells, an immortalized rat brain
endothelium cell expressing high levels of LAT-1, as
an in vitro model to assess the effect of GTS on KYN
uptake. As shown in Figure 8A, GTS had no effect on
KYN uptake in rBE4 cells, whereas a competitive inhi-
bitor of LAT-1, BCH (400 μM), significantly decreased
the uptake of KYN. Furthermore, mRNA expression of
LAT1 and its mediated KYN uptake in rBE4 cells were
not influenced by LPS (10 μg/ml) and TNF-a (20 ng/
ml) exposure for 24 h (data not show).
Figure 5 Effects of GTS on peripheral kynurenine levels and
kynurenine/tryptophan ratio. Kynurenine and tryptophan
concentrations were determined by high-performance liquid
chromatography in plasma (n = 10 mice for each group). The data
are expressed as mean ± SEM. For statistical significance, a: p < 0.01
compared with the vehicle/saline group, b: p < 0.05 compared with
the vehicle/LPS group. c: p < 0.01 or p < 0.05 compared with the
LPS/GTS group.
Figure 6 Pharmacokinetics and brain distribution of GTS in
LPS-challenged mice. GTS was administered by an oral route (200
mg/kg, once daily) for 6 days. On the 7
th day, GTS and LPS (i.p.)
were administrated simultaneously. Figure.6A represents plasma
concentration-time curves for the major ginsenosides (Rb1, Rb2,
Rb3, Rc, Rd, Re, and Rg1) in GTS (n = = 3-4 mice per time point).
Figure.6B shows the pharmacokinetic parameters of these
ginsenosides including maximal concentration (Cmax), time to reach
maximal concentration (Tmax), half-life time (T1/2), mean retention
time (MRT) and area under the curve (AUC). Figure.6C shows a low
brain exposure to these ginsenosides, the concentrations of these
ginsenosides were all less than 20 ng/g wet tissue. The data are
expressed as mean ± SD.
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model to determine the effects of GTS on regulating
IDO activity. Results (Figure 8B) show that GTS had no
effect on IDO activity even at a high concentration of
100 μg/ml. In contrast, berberine, a newly identified
IDO inhibitor, could significantly decrease production of
KYN in A549 cells [40].
Discussion
Activation of the innate immune system and subsequent
release of proinflammatory cytokines may contribute to
the development of neuropsychiatric disorders, in parti-
cular depression [41], which can be exemplified by the
high prevalence of depression in some patients with per-
ipheral inflammatory disorders [20]. Systemic inflamma-
tion can influence the CNS through both direct and
indirect pathways [41]; proinflammatory cytokines like
IL-1b,I L - 6 ,a n dT N F - a c a ng a i na c c e s st h r o u g hr e l a -
tively permeable areas of the blood-brain barrier [42,43],
and activation of the vagal nerve afferent pathway may
also account for CNS inflammation originating from the
periphery [44]. Emerging evidence suggests the existence
of cross-talk between peripheral and central inflamma-
tion, which prompted us to hypothesize that a periph-
eral anti-inflammatory strategy could be useful for the
therapy of inflammation-related CNS diseases.
The ‘ginseng paradox’ between its poor brain distribu-
tion and demonstrated neuroprotective effects has been
long-standing, but the mysteries behind it remain elu-
sive. Based on the close link between inflammation and
depression, we hypothesized that the peripheral anti-
inflammation activity of ginsenosides might explain the
majority of its anti-depression efficacy. Using a periph-
eral LPS-challenged depression model, we demonstrate
that GTS treatment significantly improves depression-
like behaviors, as evidenced from the sucrose preference
t e s t ,F S T ,T S T ,a n dt h ed e t e r mination of plasma corti-
costerone levels, all of which are typical methods used
for characterizing depression [45,46]. In addition, we
showed that GTS treatment could significantly inhibit
LPS-induced production of multiple proinflammatory
cytokines in both the brain and the periphery in mice,
and in Raw264.7 cell cultures in vitro. LPS-induced
enhancement of IDO expression/activity, an important
mediator between inflammation and depression, was sig-
nificantly ameliorated by GTS treatment. In line with
previous findings [47,48], most of the ginsenosides were
f o u n dt ob ea l m o s tc o m p l e t e l ye x c l u d e df r o mt h eb r a i n
by the BBB. GTS had no direct effect on IDO activity or
KYN transport. Our study strengthens an important
concept that peripheral anti-inflammation strategies
could be useful for therapy of inflammation-related
depression and possibly other CNS diseases.
Anti-inflammation becomes an attractive therapeutic
strategy for the treatment of depression, and has indeed
been examined at both pre-clinical and clinical levels
[20]. Minocycline significantly attenuates LPS-induced
neuroinflammation and consequent depression-like
behavior in mice [13]. Diclofenac sodium, a non-steroi-
dal anti-inflammatory drug, has been shown to be effec-
tive against LPS-induced basic reward behaviors and
HPA-axis activation in rats [49]. In view of the fact that
such drugs are readily accessible to the CNS, it remains
unclear whether a peripheral anti-inflammation strategy
Figure 7 GTS inhibits production of proinflammatory cytokines in LPS-stimulated RAW264.7 cells. The murine macrophage cell line,
Raw264.7 cells, was used to verify potential peripheral anti-inflammatory effects of GTS. Profiles of IL-6 and TNF-a are shown in Figures 7A and
7B (n = 3). The data are expressed as mean ± SEM. For statistical significance, ## p < 0.01 compared with the no treated RAW264.7 cells, *p <
0.05 **p < 0.01 compared with the LPS (100 ng/ml) treated RAW264.7 cells.
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vior. The anti-depression effect of minocycline was pre-
sumed to originate mainly from its activity on inhibiting
LPS-challenged microglial activation, based on the find-
ing that brain but not plasma IL-1b levels were restored
toward normal with minocycline treatment [33,50].
Although a previous study showed that GTS could also
inhibit activation of microglia in mouse brain inflamed
by LPS [27], this effect more likely originated from its
peripheral anti-inflammatory activity because GTS
would be unlikely to achieve an effective concentration
in microglia cells in vivo. In the present study, we found
that GTS treatment significantly reduced all the tested
pro-inflammatory cytokines in both brain and plasma.
In contrast to minocycline, most of the ginsenosides
contained in GTS are only poorly accessible to brain.
Our results indicate that, even in LPS-challenged mice,
Rb1, Rb2/Rb3, Rc, and Rd are detectable but at extre-
mely low levels in brain after intragastric administra-
t i o n so fG T Sa tad o s eo f2 0 0m g / k g .T h em a x i m u m
concentrations of such ginsenosides detected in brain
were about 20 ng/g tissues, which is far below that
needed to exert anti-inflammation effects as observed in
various in vitro studies (10-100 μM) [27,51,52]. The pos-
sibility of brain distribution of some active metabolites
of ginsenoside, like compound K, was also excluded by
using powerful LC/MS-IT-TOF analysis [53]. Neverthe-
less, we cannot exclude the possibility that low levels of
brain ginsenosides could contribute to the overall anti-
depression efficacy of GTS, because the in vitro observa-
tions may not be directly translatable to in vivo out-
comes. In spite of this limitation, results obtained from
this study strongly suggest that the peripheral anti-
inflammatory activities of GTS explain the majority of
its effects on neuroinflammation and its consequent
anti-depression efficacy.
To further verify the anti-inflammation effects of GTS,
a LPS-stimulated murine macrophage cell (Raw264.7)
model was used. The results reveal that GTS, at a con-
centration range of 5-100 μg/ml, can significantly inhibit
LPS-induced secretion of TNF-a and IL-6; the effective
concentrations observed in this in vitro study are com-
parable with plasma exposure levels of ginsenosides.
The maximum concentrations achieved for the four
major ginsenosides (Rb1, Rb2/Rb3, Rc, and Rd) reached
levels above 1 μg/ml, and the elimination half-life times
are longer than 20 h in plasma. These results suggest
that systemic exposure levels of ginsenosides could be
sufficient to exert peripheral anti-inflammatory activities.
Although the detailed molecular mechanisms connect-
ing inflammation and depression remain largely unclear,
it is acknowledged that IDO is an important mediator
linking inflammation and depression. Proinflammatory
cytokines, in particular IFN-g and TNF-a,a r et h em a i n
inducers of IDO activation [14,54]. IDO activation
results in diverting TRP from synthesis of 5-hydroxy-
tryptophan (5-HTP) and 5-hydroxytryptamine (5-HT) to
the generation of TRP metabolites such as quinolinic
acid, which is known to be neurotoxic and thereby may
lead to depression-like behaviors through both serotonin
and glutamate pathways [41,55]. The IDO antagonist, 1-
methyltryptophan (1-MT), prevents development of
depression-like behaviors in LPS-challenged mice, pro-
viding strong evidence for a pivotal role of IDO activa-
tion in inflammation-related depression. We found that
both hippocampal IDO mRNA levels and plasma IDO
activities (KYN/TRP ratio) are significantly reduced by
GTS treatment. However, GTS showed no direct inhibi-
tory effect on IDO activity in hIFN-g-stimulated A549
cell cultures, indicating that the observed IDO-
Figure 8 GTS has no direct effect on LAT-1-mediated
kynurenine transport across the BBB and IDO-mediated
kynurenine production. rBE4 cells were used as an in vitro model
to assess the effects of GTS on KYN transport. A549 cells, stimulated
with hIFN-g, were used as a model to determine GTS effects on IDO
activity. Figure.8A shows that GTS has no effect on LAT-1-mediated
kynurenine uptake in rBE4 cells (n = 3). Figure.8B reveals that GTS
has no effect on IDO-mediated kynurenine production in A549 cells
based on an IDO inhibition assay (n = 3). The data are expressed as
mean ± SEM. For statistical significance, ## p < 0.01 compared with
the no treated A549 cells, **p < 0.01 compared with the kynurenine
(40 μM) loaded rBE4 cells or hIFN-g treated A549 cells.
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peripheral anti-inflammatory activity.
A recent study showed that exogenous administration
of kynurenine to naive mice is able to induce depres-
sion-like behavior, suggesting an important role for
kynurenine in mediating IDO activation-induced depres-
sion [13]. It is important to note that the increased
kynurenine levels in brain originate exclusively from the
periphery in systemic inflammation models [56]. Upon
innate immune system stimulation, the expression and
activity of IDO in vascular endothelial cells and macro-
phages is significantly enhanced, which leads to high
plasma levels of kynurenine [13,56], and parallel
enhancement of brain kynurenine levels via LAT-1-
mediated transport [57]. In the uptake experiment per-
formed with rBE4 cells, we found that GTS has no
direct effect on kynurenine uptake. In addition, GTS
treatment had no effect on exogenous kynurenine
administration-induced depression-like behavior (data
not shown). Together, our results suggest that GTS pre-
treatment-induced decreases in kynurenine levels in
brain are largely due to reduced peripheral production
of kynurenine caused by the peripheral anti-inflamma-
tory activity of GTS.
In view of the fact that the BBB and its constituent
cells, including microvascular endothelial cells, peri-
cytes, and microglia, may play an important role in
mediating crosstalk between peripheral and central
inflammation signals, it would be of great interest in a
future study to determine whether GTS could interfere
with BBB-mediated crosstalk between periphery and
CNS.
In conclusion, the present study suggests that GTS
could be of therapeutic benefit in inflammation-related
depression, and that such an effect largely originates
from its peripheral anti-inflammation activities. Figure
9 summarizes the probable mechanisms of GTS effects
on ameliorating LPS-induced depression-like behaviors.
The present findings not only provide a scientific
explanation for the long-standing ‘ginseng paradox’
between its poor brain distribution and its demon-
strated neuroprotective effects, but more importantly,
strengthens an important concept that peripheral anti-
inflammatory strategies may be useful for the therapy
of inflammatory CNS diseases like depression. Such a
concept is also supported by the recent finding that
etanercept, a recombinant fusion protein of human
tumor necrosis factor-a (TNF-a) receptor and immu-
noglobulin G1, can relieve fatigue and symptoms of
depression associated with CNS inflammatory disease
or peripheral inflammation [58-60] despite its poor
transport across the BBB [61]. More recently, a periph-
erally restricted inhibitor (URB937) of fatty acid amide
hydrolase has been found to be capable of attenuating
behavior responses in various rodent models of pain
and, meanwhile, avoiding unwanted side effects from
activation of brain cannabinoid receptors [62]. In com-
bination with emerging evidence, our results highlight
an important notion that the intervention of peripheral
targets may be an attractive strategy for the treatment
of CNS disorders; such a notion may open up a pro-
mising avenue for the rational design of CNS drugs
with reduced central side effects.
Abbreviations
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Figure 9 Proposed anti-depression mechanisms of GTS in the
LPS-induced depression model. Peripheral LPS administration
results in production of cytokines, including IL-1b, IL-6, IFN-g), and
TNF-a. These peripheral inflammation signals may be transmitted to
the brain through humoral and neural pathways, leading to
neuroinflammation. The peripheral and brain cytokines induce
transcription and enzymatic activity of IDO, and lead to high levels
of kynurenine in periphery and brain. As reported previously,
peripheral kynurenine is the main source of increased kynurenine
levels in LPS-treated mouse brain through LAT-1-mediated
kynurenine active transport across the BBB. Increased kynurenine
may metabolize to neurotoxic metabolites like quinolinic acid, thus
influencing glutamatergic neurotransmission. Increased IDO activity
may also decrease tryptophan availability, thus impacting
serotonergic neurotransmission. Inflammation-associated disorder of
serotonergic and glutamatergic neurotransmission ultimately
induces depression-like behavior. GTS, a well known tonic traditional
medicine with poor brain distribution, can improve depression-like
behavior in LPS-challenged mice. This seemingly paradoxic
concentration-effect relationship could be partially explained by an
indirect periphery-to-brain pathway: GTS inhibits LPS-induced
peripheral inflammation, thus decreasing neuroinflammation. The
inhibition of peripheral inflammation could also partially reverse
activation of IDO in the periphery, thus decreasing levels of
kynurenine in brain which derive exclusively from periphery in this
model, thus ameliorating depressive symptoms.
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